CBIO, a biopharmaceutical company in its industry, demonstrates strong financial compliance with Shariah screening criteria, passing all major ratio thresholds under AAOIFI, MSCI, and S&P standards. However, due to its small market capitalization and low liquidity, it is not included in any major Shariah-compliant indices. The core business activities in rare disease therapeutics are permissible, with no non-compliant revenue identified. Overall, while financially compliant, index exclusion leads to a non-compliant classification for investment purposes. Purification is required for minor interest income exposure.